NASDAQ:ANIPANI Pharmaceuticals Stock Price, Forecast & News

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ANIP stock has decreased by 20.7% and is now trading at $30.38.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ANI Pharmaceuticals.

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ANI Pharmaceuticals.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) released its quarterly earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.57 by $0.12. ANI Pharmaceuticals had a negative net margin of 0.67% and a positive return on equity of 23.92%. During the same period in the previous year, the business posted $1.44 earnings per share.
View ANI Pharmaceuticals' earnings history.

3 equities research analysts have issued 1 year price targets for ANI Pharmaceuticals' stock. Their forecasts range from $40.00 to $58.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 51.4% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals.

News coverage about ANIP stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about ANI Pharmaceuticals.

ANI Pharmaceuticals saw a decrease in short interest in June. As of June 30th, there was short interest totaling 559,500 shares, a decrease of 10.1% from the June 15th total of 622,200 shares. Based on an average daily trading volume, of 128,300 shares, the days-to-cover ratio is presently 4.4 days. Currently, 5.8% of the company's stock are sold short.
View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include Revance Therapeutics (RVNC), Rocket Pharmaceuticals (RCKT), MacroGenics (MGNX), Akebia Therapeutics (AKBA), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Zymeworks (ZYME), Intra-Cellular Therapies (ITCI), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Zogenix (ZGNX), Mersana Therapeutics (MRSN), Amneal Pharmaceuticals (AMRX) and Epizyme (EPZM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), AbbVie (ABBV), Cisco Systems (CSCO), Intel (INTC) and NXP Semiconductors (NXPI).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.16%), Russell Investments Group Ltd. (0.81%), Principal Financial Group Inc. (0.61%), LSV Asset Management (0.56%), WINTON GROUP Ltd (0.35%) and Regent Investment Management LLC (0.32%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Principal Financial Group Inc., Seizert Capital Partners LLC, LSV Asset Management, Regent Investment Management LLC, Truvestments Capital LLC, and Texas Permanent School Fund.
View insider buying and selling activity for ANI Pharmaceuticals.

ANIP stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., WINTON GROUP Ltd, UBS Group AG, Centric Wealth Management, Swiss National Bank, Mesirow Financial Investment Management Inc., Cadence Capital Management LLC, and Strs Ohio. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $30.38.

ANI Pharmaceuticals has a market capitalization of $374.59 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]